The first half of 2015 has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all showing no signs of slowing down, according to EP Vantage's Pharma & Biotech Half-Year Review 2015.

Key highlights include:

• The year started with one of the biggest venture rounds ever with the $450 million Moderna Therapeutics managed to secure from its investors in January 

• VCs gifted $3.8 billion to companies at the half-year point signifying that 2015 could once again raise the bar in terms of funding totals

• On average, the 32 floats this year yielded only a three percent discount from the listed range, and increased in value by 23 percent since their IPOs